Gene silencing therapies are estimated at 46.0% by therapy type in 2026, with hereditary transthyretin amyloidosis with polyneuropathy at 58.0% by disease type and intravenous administration at 42.0% by route. Earlier genetic confirmation supports adoption but specialist capacity and reimbursement review restrict timely access across national treatment pathways.
Familial Amyloid Polyneuropathy Market Analysis By Disease TypeFamilial Amyloid Polyneuropathy Market Analysis By Distribution ChannelFamilial Amyloid Polyneuropathy Market Analysis By End UserFamilial Amyloid Polyneuropathy Market Analysis By Route Of AdministrationFamilial Amyloid Polyneuropathy Market Opportunity Matrix Growth Vs ValueFamilial Amyloid Polyneuropathy Market Breakdown By Therapy Type, Disease Type, And Region